ATE101162T1 - Durch cys-kodon modifizierte dns. - Google Patents

Durch cys-kodon modifizierte dns.

Info

Publication number
ATE101162T1
ATE101162T1 AT86907171T AT86907171T ATE101162T1 AT E101162 T1 ATE101162 T1 AT E101162T1 AT 86907171 T AT86907171 T AT 86907171T AT 86907171 T AT86907171 T AT 86907171T AT E101162 T1 ATE101162 T1 AT E101162T1
Authority
AT
Austria
Prior art keywords
dna modified
cys codon
dna sequence
exhibit
codon
Prior art date
Application number
AT86907171T
Other languages
English (en)
Inventor
Hospital Univ
Original Assignee
Hospital Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital Univ filed Critical Hospital Univ
Application granted granted Critical
Publication of ATE101162T1 publication Critical patent/ATE101162T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT86907171T 1985-11-13 1986-11-13 Durch cys-kodon modifizierte dns. ATE101162T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79816385A 1985-11-13 1985-11-13
PCT/US1986/002444 WO1987002987A1 (en) 1985-11-13 1986-11-13 Cys codon-modified dna

Publications (1)

Publication Number Publication Date
ATE101162T1 true ATE101162T1 (de) 1994-02-15

Family

ID=25172688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86907171T ATE101162T1 (de) 1985-11-13 1986-11-13 Durch cys-kodon modifizierte dns.

Country Status (6)

Country Link
EP (1) EP0246307B1 (de)
JP (1) JP2635035B2 (de)
AT (1) ATE101162T1 (de)
AU (1) AU6733287A (de)
DE (1) DE3689620T2 (de)
WO (1) WO1987002987A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US5084559A (en) * 1987-03-27 1992-01-28 Repligen Corporation Protein a domain mutants
US5827934A (en) * 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5290914A (en) * 1988-04-28 1994-03-01 Mycogen Corporation Hybrid diphtheria-B.t. pesticidal toxins
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
NZ232900A (en) * 1989-03-22 1993-08-26 Merck & Co Inc Pseudomonas exotoxin a, pe 40 domain derivatives
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5767072A (en) * 1989-09-14 1998-06-16 Board Of Regents, The University Of Texas System Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
WO1991013090A1 (en) * 1990-03-02 1991-09-05 Diane Williams Improved chimeric toxins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US6632928B1 (en) 1997-03-05 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
EP0968282A2 (de) * 1997-03-05 2000-01-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vektore und verfahren zur expression mutierter proteinen
FR2827606A1 (fr) * 2001-07-20 2003-01-24 Pf Medicament Nouveaux derives d'anatoxines diphteriques et leur utilisation comme porteur

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833174B (en) * 1982-05-05 1984-08-29 Genentech Inc Human tissue plasminogen activator
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US4468382A (en) * 1982-07-15 1984-08-28 New England Medical Center, Inc. Polypeptide-toxin hybrid protein

Also Published As

Publication number Publication date
EP0246307A1 (de) 1987-11-25
WO1987002987A1 (en) 1987-05-21
JPS63501799A (ja) 1988-07-21
DE3689620T2 (de) 1994-06-16
EP0246307A4 (de) 1989-06-13
DE3689620D1 (de) 1994-03-17
EP0246307B1 (de) 1994-02-02
JP2635035B2 (ja) 1997-07-30
AU6733287A (en) 1987-06-02

Similar Documents

Publication Publication Date Title
ATE101162T1 (de) Durch cys-kodon modifizierte dns.
DE3586206D1 (de) Metoprololsuccinat und dieses enthaltende pharmazeutische zusammensetzung.
DE3686397D1 (de) Kovalent gebundene polypeptid enthaltende zellmodulatoren.
DE3580460D1 (de) Gemischte phenylendiester als persaeurevorlaeufer.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
DK590085D0 (da) Bicycliske heteroarylpiperazinderivater og fremgangsmaade til deres fremstilling
DE3680583D1 (de) Elektrodenzusammensetzung.
AU5092185A (en) Osmotic concentration by membrane
AU5233686A (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
FI860541A0 (fi) Hybridprotein och detta kodande fusionerad gen.
DK405785D0 (da) Antistof, cellelinje, der producerer antistoffet, og sammensaetning indeholdende antistoffet
DE68908982D1 (de) Mikrobiologische Kontrolle der Schwefelwasserstoffproduktion durch sulfatreduzierende Bakterien.
DE3581336D1 (de) Polypeptid verwandt mit alpha-hanp.
BR9204788A (pt) Sequencia de dna,proteina,gene quimerico,vetor,celula transformada e planta transformada
DE69535316D1 (de) Als lerk6 bezeichnetes cytokin
DK502585A (da) Stativ til forholdsvis tunge haandvaaben
DE3577108D1 (de) Modifizierte urokinase-zusammensetzung.
PT84011A (fr) Procede de preparation de nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant de calcium de l:organisme
FI862019A7 (fi) B-glukanaasientsyymin valmistus sieniä fermentoimalla.
ES289169U (es) Destornillador con brazo de potencia
DK137184A (da) Sut til sutteflaske
MX7124E (es) Procedimiento para preparar enzimas modificadas biologicamente activas,mediante modificacion quimica de proteinas naturales
ES283600U (es) Silla de suspension colgante infantil
IS3036A7 (is) Hlutur til reykinga.
ATE54544T1 (de) Natriumarmes, als kochsalzsubstitut geeignetes salzgemisch.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time